IcotrokinraIL-23R Psoriasis Drug Profile
Icotrokinra
IL-23R Psoriasis Drug Profile
The first oral synthetic cyclic peptide targeting IL-23R, approved by the FDA on March 17, 2026 for plaque psoriasis. Developed by Janssen Biotech with 26 clinical trials and 9 core patents — a first-in-class mechanism in immune receptor modulation.
First oral IL-23R cyclic peptide — FDA approved March 2026
Icotrokinra is a synthetic cyclic peptide drug targeting the IL-23 receptor (IL-23R), developed by Janssen Biotech, Inc. On March 17, 2026, it received FDA approval for the treatment of plaque psoriasis, making it the first oral agent of its class to reach this receptor mechanism.
Unlike the injectable biologics that dominate current psoriasis therapy — which block IL-23 at the ligand level — icotrokinra acts directly at the receptor, representing a novel pharmacological approach to interrupting the IL-23/IL-17 immune axis that underlies plaque psoriasis pathophysiology. Its oral route of administration distinguishes it from every approved biologic in this pathway.
| Drug name | Icotrokinra |
| Target | IL-23R (Interleukin-23 receptor) |
| Drug type | Synthetic cyclic peptide |
| Developer | Janssen Biotech, Inc. |
| Indication | Plaque psoriasis |
| Approval region | United States (FDA) |
| Approval date | March 17, 2026 |
| Core patents | 9 |
| Clinical trials | 26 (Immune System Diseases) |
26 clinical trials in Immune System Diseases
According to the Synapse database, icotrokinra’s development program primarily focuses on the field of Immune System Diseases, with 26 clinical trials conducted across its development history. This depth of clinical investigation reflects the program’s broad exploration of dose, formulation, and patient population across multiple psoriasis severity strata prior to the pivotal registration trials.
IL-23R: a receptor-level intervention in the IL-23/IL-17 axis
Plaque psoriasis is a chronic, immune-mediated inflammatory skin disease characterised by dysregulated interleukin signalling. The IL-23/IL-17 cytokine axis is the central driver of the inflammatory cascade responsible for the characteristic erythematous, scaly plaques. Existing approved biologics targeting IL-23 act at the ligand (p19 or p40 subunit), blocking cytokine activity before receptor engagement.
Interleukin-23 receptor (IL-23R) is a type I transmembrane protein that forms a heterodimeric receptor complex. As the terminal signalling node in this axis, IL-23R represents a mechanistically distinct intervention point — inhibiting signalling regardless of which upstream cytokine or combination drives pathway activation. Icotrokinra’s cyclic peptide structure allows oral bioavailability at this receptor target, a pharmacological achievement not previously demonstrated for this class.
Oral cyclic peptide at IL-23R
Icotrokinra is a synthetic cyclic peptide that directly blocks IL-23R signalling. Cyclic peptides offer cell membrane permeability and oral bioavailability not achievable with conventional linear peptides, enabling a small-molecule-like dosing route for a receptor target previously served only by injectable antibodies.
IL-23R · Cyclic peptide · OralPlaque psoriasis: dysregulated IL signalling
Plaque psoriasis affects an estimated 2–3% of the global population. The dysregulated IL-23/IL-17 axis drives keratinocyte hyperproliferation and neutrophil recruitment, producing the characteristic plaques. IL-23R blockade interrupts this cycle at the receptor level, offering a mechanistically differentiated approach to the established biologic standard of care.
Plaque psoriasis · Immune-mediatedFour registration trials supported the FDA approval
Icotrokinra’s FDA approval was based on results from NCT06220604, NCT06143878, NCT06095115, and NCT06095102.
The approval package comprised four clinical trials covering the key registration endpoints required by FDA for moderate-to-severe plaque psoriasis: PASI response rates (PASI 75, PASI 90, PASI 100), Investigator Global Assessment (IGA), and safety profile. The four trial NCT identifiers reflect a broad programme spanning dose-finding, placebo-controlled, and potentially head-to-head or long-term extension designs consistent with the scope of a full psoriasis registration package.
| NCT06220604 | Pivotal registration trial — plaque psoriasis |
| NCT06143878 | Pivotal registration trial — plaque psoriasis |
| NCT06095115 | Pivotal registration trial — plaque psoriasis |
| NCT06095102 | Pivotal registration trial — plaque psoriasis |
16 drugs targeting IL-23R — icotrokinra as the only oral agent
According to the Synapse database, there are currently 16 drugs targeting IL-23R. Icotrokinra is the first and only oral cyclic peptide in this class to receive regulatory approval.
Oral vs injectable: a structural advantage
All previously approved IL-23 pathway biologics require subcutaneous or intravenous administration. Icotrokinra’s oral cyclic peptide format creates a differentiated patient-preference and market access profile, particularly in mild-to-moderate segments where biologic initiation faces adherence and reimbursement friction.
Receptor-level mechanism: a distinct position
Existing approved IL-23 agents (risankizumab, guselkumab, tildrakizumab) block the p19 subunit of IL-23 at the ligand level. Icotrokinra’s receptor-level blockade offers a mechanistically distinct position that may complement or succeed ligand-level therapies in patients with inadequate response to the biologic standard of care.
Cyclic peptide modality: implications beyond psoriasis
Icotrokinra’s approval validates oral cyclic peptides as a viable modality for immune receptor targets that were previously considered inaccessible to small molecules. This opens a development pathway for cyclic peptide programs targeting other cytokine receptors — with potential implications for atopic dermatitis, IBD, and systemic lupus pathways sharing upstream IL-23 biology.
Competitive pressure on established IL-23 biologics
With 16 drugs targeting IL-23R and the addition of an approved oral option, established injectable biologics in the psoriasis space — including risankizumab, guselkumab, and tildrakizumab — face growing competition for biologic-naive and biologic-experienced patients, particularly in oral-preference patient segments.
Icotrokinra — key questions answered
Icotrokinra is a synthetic cyclic peptide drug targeting IL-23R developed by Janssen Biotech, Inc. On March 17, 2026, it received FDA approval for plaque psoriasis, becoming the first oral agent of its class targeting the IL-23 receptor.
According to the Synapse database, icotrokinra has been studied in 26 clinical trials, primarily in the field of Immune System Diseases.
According to the Synapse database, there are 9 core patents associated with icotrokinra.
Icotrokinra was approved based on NCT06220604, NCT06143878, NCT06095115, and NCT06095102.
According to the Synapse database, there are currently 16 drugs targeting IL-23R, making icotrokinra’s oral cyclic peptide mechanism a differentiated entry in this competitive class.
Icotrokinra is a synthetic cyclic peptide that directly targets the IL-23 receptor (IL-23R), whereas existing injectable biologics block IL-23 at the ligand level. This receptor-level mechanism and its oral route of administration distinguish it from the injectable antibody class.
Data on this page is sourced from the PatSnap Synapse database and is for reference only. Dataset represents a snapshot of available records as of March 2026.